Preview the most anticipated trials of ACC 2025 with Nicolas Van Migehem and Joost Daemen in the latest episode of View from the Thoraxcenter. 

The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.

ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago. View the full programme here.

Late-Breaking Clinical Trials I (Session 102)

Saturday 29th March, 09:30 – 10:30am CST

• Primary and Secondary Outcomes of the Women's Ischemia Trial to Reduce Events in Non-Obstructive Coronary Artery Disease – Presented by Dr Carl Pepine
• The Effect of Once-weekly Subcutaneous Semaglutide on Functional Capacity in People With Type 2 Diabetes and Peripheral Artery Disease: Primary Results From the Phase 3b, Randomized, Placebo-Controlled, Double Blind Stride Trial – Presented by Dr Marc Bonaca
• Extended Anticoagulant Treatment With a Reduced Versus Full Dose Apixaban in Patients With Cancer-Associated Venous Thromboembolism: The API-CAT Study – Presented by Prof Isabelle Mahe

Late-Breaking Clinical Trials II (Session 104)

Saturday 29th March, 13:30 – 14:30pm CST

• Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial – Presented by Dr Darren McGuire
• Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen – Presented by Dr Luke Laffin
• Development and External Validation of a Deep Learning Electrocardiogram Model For Risk Stratification of Coronary Revascularization Need in the Emergency Department – Presented by Dr Antonius Buescher
• Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation – Presented by Dr Sergio Roubin

Late-Breaking Clinical Trials III (Session 105)

Saturday 29th March, 15:00 – 16:00pm CST

• Efficacy of Rivaroxaban Versus Warfarin in Patients With Acute Left Ventricular Thrombus Following Myocardial Infarction: An Open-Label Randomized Controlled Trial RIVAWAR Trial Investigators – Presented by Dr Jehangir Shah
• Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients With Coagulopathy — Results From a Phase 3, Randomized, Active-Control Study – Presented by Dr Keyvan Karkouti
• The Main Results of the Phase 3 Reverse-it Trial – Presented by Dr Deepak Bhatt
• Stratified Randomization Study to Compare Different Duration of Dual Antiplatelet Therapy After Coronary Stenting in Either High or Low Bleeding Risk Population – Presented by Dr Hyo-Soo Kim

Late-Breaking Clinical Trials IV (Session 106)

Sunday 30th March, 08:00 – 09:00am CST

• Comparative Effectiveness of Mobile Integrated Health Versus a Transitions of Care Coordinator in Patients With Heart Failure: Results From the MIGHTy-Heart Trial – Presented by Dr Ruth Creber
• Liberal Fluid Intake Versus Fluid Restriction in Chronic Heart Failure – Presented by Dr Roland Kimmenade
• The Equiox Study: Evaluating Pulse Oximeter Bias Across a Range of Skin Pigment in Critically Ill Adults – Presented by Dr Carolyn Hendrickson
• Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF2) Trial – Presented by Prof Stefan Anker

Late-Breaking Clinical Trials V (Session 107)

Sunday 30th March, 10:00 – 11:00am CST

• Routine Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation: The British Heart Foundation (BHF) PROTECT-TAVI Trial – Presented by Prof Rajesh Kharbanda
• Clinical And Echocardiographic Outcomes Among the First 500 Patients Treated With a Dedicated Transcatheter Aortic Valve For Pure Aortic Regurgitation in the Align-AR Clinical Trial – Presented by Dr Raj Makkar
• 5-year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis – Presented by Dr Michael Reardon
• Comparison of Angiography-Derived Fractional Flow Reserve-Guided and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention Strategies: The FLAVOUR II Trial – Presented by Dr Jian-An Wang

Late-Breaking Clinical Trials VI (Session 108)

Sunday 30th March, 11:30 – 12:30pm CST

• Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The Triluminate Pivotal Trial – Presented by Prof Saibal Kar
• Fractional Flow Reserve Guided Percutaneous Coronary Intervention Compared With Bypass Surgery: Final 5 Year Results of the Fractional Flow Reserve Versus Angiography For Multivessel Evaluation 3 Trial – Presented by Dr William Fearon
• Clopidogrel Versus Aspirin For Long-Term Maintenance Monotherapy in Patients With High Ischemic Risk After Percutaneous Coronary Intervention – Presented by Dr Joo-Yong Hahn
• Alliance For Secondary Prevention After an Acute Coronary Syndrome – Presented by Dr Giulia Magnani

Featured Clinical Research I (Session 109)

Sunday 30th March, 13:30 – 14:30pm CST

• Pre-Operative Treatment With Digifab Prevents Post-Operative Acute Kidney Injury (AKI) in Patients at High Risk For AKI Undergoing Cardiac Bypass Graft Surgery – Presented by Dr Stephen Gottlieb
• Catheter Ablation Vs. Risk Factor Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Study – Presented by Dr Pavel Osmancik
• An Extended Duration Small-Interfering RNA Targeting Lipoprotein(a): The Alpaca Phase 2 Trial of Lepodisiran With 540 Day Follow-Up – Presented by Dr Steven Nissen
• Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: The Detect AS Trial – Presented by Dr Sammy Elmariah

Featured Clinical Research II (Session 110)

Sunday 30th March, 15:30 – 16:30pm CST

• Herzcheck - Mobile CMR to Improve Subclinical Heart Failure Detection in Rural Areas – Presented by Prof Sebastian Kelle
• A Double Blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients With HFrEF: Principal Results From the CardiAMP-HF Trial – Presented by Dr Amish Raval
• Early Intra-aortic Balloon Pump in Heart Failure Complicated by Cardiogenic Shock: The Altshock-2 Randomized Clinical Trial – Presented by Dr Alice Sacco
• Health 360x.ai Registry: AI Enabled Equitable Access To Point of Care Decentralized Clinical Trials – Presented by Dr Elizabeth Ofili

Featured Clinical Research III (Session 111)

Sunday 30th March, 17:00 – 18:00pm CST

• Modified Application of Cardiac Rehabilitation For Older Adults (MACRO) – Presented by Dr Daniel Forman
• Survival Outcomes After Sudden Cardiac Arrest in Young Competitive Athletes From the United States – Presented by Dr Bradley Petek
• Lifetime Benefit by Control of Modifiable Risk Factors – Presented by Prof Christina Magnussen
• Cardiac Arrest During Long-Distance Running Races: 2010-2023 – Presented by Dr Jonathan Kim

Featured Clinical Research IV (Session 112)

Monday 31st March, 09:00 – 10:00am CST

• Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, Obesity and Chronic Kidney Disease: The Summit Trial – Presented by Dr Milton Packer
• Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial – Presented by Dr Matthew Budoff
• Effects of Dapagliflozin on Echocardiographic Measures of Cardiac Structure and Function in Patients With Chronic Kidney Disease: The DECODE-CKD Trial – Presented by Dr Katja Bartholdy
• Effect of Solbinsiran, a Small Interfering RNA Targeting ANGPTL3, on Biomarkers of Major Adverse Cardiovascular Events in Adults With Mixed Dyslipidemia: A Randomized Phase 2 Trial – Presented by Prof Kausik Ray

Featured Clinical Research V (Session 113)

Monday 31st March, 11:00 – 12:00pm CST

• New Insights From the Early and Delayed Aortic Valve Replacement Implant Patients: A Sub-Analysis of the Early TAVR Trial – Presented by Dr Philippe Genereux
• Alternative Antithrombotic Pathways in Acute Myocardial Infarction With Large Thrombus Burden: A Randomized Trial ARISE-ARMYDA 7 – Presented by Dr Marco Mennuni
• Efficacy and Safety of Azd0780, an Oral Small Molecule PCSK9 Inhibitor For Treatment of Hypercholesterolemia: Results From a Ph2b Randomized Placebo-Controlled Clinical Trial – Presented by Dr Michael Koren
• Effectiveness of the 0/1-hour Algorithm For Chest Pain Assessment in Patients Presenting to the Emergency Department: A Multicenter Study in Asian Countries – Presented by Prof Kenji Inoue

References

ACC 25. Late-Breaking Clinical Trials. 2025. https://accscientificsession.acc.org/en/Plan-Your-Program/Late-Breakers#:~:text=Late%2DBreaking%20Clinical%20Trials&text=With%20six%20Late%2DBreaking%20Clinical,on%20the%20newest%20clinical%20research (accessed 31 January 2025).